Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Patrick Travis (NPI 1104897099)

Field	Value
Entity Type	Individual
Organization	Patrick Travis
Address	3901 Parkway Cir Ste 100
City	Springdale
State	AR
ZIP	72762
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 30, 2006

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: reported Medicare lifetime revenue is $3.3M and there is no Medicaid billing on file. The absence of any Medicaid claims indicates the practice’s commercial footprint (at least in Medicaid) is minimal or not captured in state files, so analyses should treat Medicare as the dominant and only public-payer revenue stream in the dataset.

Revenue is highly concentrated in a small set of infused oncology agents: the precomputed top three Medicare codes (J9144, J9299, J9271) account for 53.8% of total Medicare revenue. Individually, J9144 contributes 20.5%, J9299 contributes 18.0%, and J9271 contributes 15.3%, identifying biologic/monoclonal antibody administration as the primary revenue drivers.

The CPT/HCPCS mix signals an oncology infusion practice that also manages diagnostics and longitudinal outpatient care. High-revenue injectable cancer therapies (J9144 daratumumab, J9299 nivolumab, J9271 pembrolizumab) together with immune globulin and biosimilar biologics suggest routine in‑office infusion services, while co‑reported PET/CT and lab codes point to integrated diagnostic workflows supporting treatment decisions.

Competitive standing for the top drug codes is modest to moderate at the national level: J9144 ranks #73 of 615 (88th percentile) and J9299 ranks #130 of 505 (74th percentile), both described as typical, unremarkable national volumes despite being above median peers; J9271 ranks #1079 of 1841 (41th percentile) and is near typical volume. In short, this provider is not a clear national leader for these agents but maintains above‑median activity on at least some high‑cost drugs.

Encounter-level billing shows an outsized role for office management: 99214 appears as an extreme outlier (ranks #5191 of 479517, 99th percentile) with 1.3K claims and $123K revenue, indicating especially high volumes of moderate‑complexity E/M visits. Complementary chemotherapy administration coding (96413) is also notably above typical national volume (94th percentile), reinforcing a workflow that pairs frequent follow‑up visits with active in‑office treatment.

High-cost diagnostic imaging is a meaningful revenue component: PET/CT codes 78815 and 78816 together generate roughly $235K in revenue and rank in the upper national percentiles (78th and 89th respectively), and A9596 (Ga‑68) and A9552 (FDG F‑18) appear on the list as well. These entries suggest either on‑site radiology services or close affiliation with high‑frequency imaging centers, supporting advanced staging and treatment monitoring for oncology patients.

Routine laboratory testing volumes are elevated relative to peers, with panel and hematology codes such as 80053, 85025, 83735, 83615, and 84100 all appearing with large claim counts and very high national percentiles (many at or near the 98th percentile). This pattern is consistent with an oncology practice that conducts frequent monitoring and point‑of‑care lab evaluation as part of ongoing cancer therapy management.

The provider has a long tenure in the NPI file (enumerated 2006-01-30, ~20 years), indicating an established practice and likely stable referral relationships. Combined with $3.3M lifetime Medicare revenue and the concentrated drug revenue profile, the data portray a mid‑sized, experienced hematology/oncology practice focused on in‑office infusion therapies, diagnostics, and frequent outpatient management visits.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

132 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	16,380	$40	$622.4K
J9299	Injection, nivolumab, 1 mg	22,800	$20	$547.2K
J9271	Injection, pembrolizumab, 1 mg	10,800	$40	$464.4K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	7,970	$40	$302.9K
J0897	Injection, denosumab, 1 mg	9,000	$20	$162K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	4,190	$40	$146.7K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	140	$1,010	$145K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,340	$90	$123K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	90	$1,010	$90K
A9596	Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie	80	$960	$81K

Showing 1–10 of 132

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 132 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Patrick Travis — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

132 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	36	40	20,700	$40	$896.3K
J9299	9	30	15,660	$20	$432.9K
J9144	1	10	10,530	$40	$361.9K
J1561	2	10	5,930	$40	$216.4K
Q5115	3	20	2,800	$30	$95.9K
J0897	29	160	2,580	$20	$89.7K
A9596	6	10	80	$850	$87.3K
78815	39	100	90	$550	$83.7K
J0885	27	40	4,070	$10	$38K
96413	27	80	380	$90	$36.6K

Showing 1–10 of 132

Related Providers

Other providers that share a Tax Identification Number (TIN) with Patrick Travis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0
Mitchell Ross	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Patrick Travis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ozark Guidance Center, Inc	AR	Community/Behavioral Health Agency	$0	$74.5M
Arkansas Childrens Northwest, Inc.	AR	Children's Hospital	$0	$48M
Arisa Health, Inc.	AR	Community/Behavioral Health Agency	$0	$14.9M
Jarvis Pediatric Therapy, Inc.	AR	Specialist	$0	$10.6M
Wendy Cassady Speech Pathology, Inc	AR	Speech-Language Pathologist	$0	$9.2M
Preferred Family Healthcare Inc	AR	Community/Behavioral Health Agency	$0	$8.1M
Kidscorp Of Fayetteville, Inc	AR	Developmental Disabilities Clinic/Center	$0	$6.9M
University Of Arkansas For Medical Sciences	AR	Developmental - Behavioral Pediatrics Physician	$0	$5.8M
Northwest Physicians LLC	AR	Obstetrics Physician	$0	$5.8M
All Aboard Pediatric Therapy	AR	Pediatric Occupational Therapist	$0	$5.3M

Patrick Travis — Billing Profile & Reimbursement Data

Sign up for Patrick Travis — Billing Profile & Reimbursement Data policy alerts

Patrick Travis — Billing Profile & Reimbursement Data

Sign up for Patrick Travis — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References